Clinical Trial: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06952530) titled 'A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2' on April 21.

Brief Summary: GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Hypertension

Intervention: DRUG: Orforglipron

Administered orally

DRUG: Placebo

placebo administered

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lilly and Company

Published by HT...